Vigil Neuroscience, Inc. (VIGL)
| Market Cap | 121.25M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -78.92M |
| Shares Out | 35.87M |
| EPS (ttm) | -2.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 73,407 |
| Open | 3.68 |
| Previous Close | 3.69 |
| Day's Range | 3.35 - 3.70 |
| 52-Week Range | 2.85 - 12.96 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 17.00 (+402.96%) |
| Earnings Date | Nov 7, 2023 |
About VIGL
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for VIGL stock is "Buy." The 12-month stock price forecast is $17.0, which is an increase of 402.96% from the latest price.
News
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
- Iluzanebart demonstrated favorable safety and tolerability, including no hematologic adverse events - - Clear CNS target engagement and downstream pharmacological activity at 20 mg/kg consistent wit...
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
– Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in ALSP on track for this quarter – – First participant dosed in Phase 1 study of VG-3927, the first and only small molec...
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease
WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
WATERTOWN, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
WATERTOWN, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg -
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer's Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to...
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 -
Vigil Neuroscience Appoints Christopher J. Silber, M.D.
WATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
- Partial clinical hold lifted by FDA on VGL101 - - Launched ALSPAware to provide access to no-cost genetic testing and counseling for ALSP - - Appointed distinguished biopharmaceutical industry leade...
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
– New genetic testing initiative designed to enable improved patient diagnosis of ALSP, a devastating, rare genetic neurodegenerative disease –
Vigil Neuroscience to Present at Stifel 2023 CNS Days
WATERTOWN, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil Neuroscience Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
– Dosed first patient in IGNITE Phase 2 clinical trial to evaluate VGL101 in patients with ALSP –
Vigil Neuroscience Announces Multiple Presentations on Lead Indication ALSP at the 2023 American Academy of Neurology Annual Meeting
WATERTOWN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Vigil Neuroscience Appoints David Gray, Ph.D., as Chief Scientific Officer and Announces Changes to Executive Team
– Dr. David Gray brings nearly 20 years of preclinical and clinical research and drug development expertise in neurological diseases –
Vigil Neuroscience Announces First Patient Dosed in the IGNITE Phase 2 Clinical Trial to Evaluate VGL101 in Patients with ALSP
First-ever interventional trial for patients with ALSP, a rare and rapidly progressing neurological disease with significant unmet medical need First-ever interventional trial for patients with ALSP, ...
Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022
CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Vigil Neuroscience Reports Third Quarter 2022 Financial Results and Provides Business Update
–Announced interim topline data from Phase 1 trial of VGL101 in healthy volunteers–
Vigil Neuroscience to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP
CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...
Vigil Neuroscience Receives FDA Fast Track Designation for VGL101 for the Treatment of Patients with ALSP
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of ...